Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UMLS:C0029463 (
osteosarcoma
)
16,637
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
The long noncoding RNA,
RHPN1
antisense RNA 1 (
RHPN1
-AS1
), performs important regulatory actions in the progression of many human cancers. In this study, we aimed to analyze
RHPN1
-AS1
expression in
osteosarcoma
(OS) and to assess the influence of
RHPN1
-AS1
knockdown on the malignant behavior of OS cells. The molecular mechanisms by which
RHPN1
-AS1
affects the oncogenicity of OS were explored too. The expression of
RHPN1
-AS1
in OS was measured by RT-qPCR. The effects of the
RHPN1
-AS1
silencing in OS cells were studied both in vitro (in a Cell Counting Kit-8 assay, apoptosis analysis, and Transwell migration and invasion assays) and in vivo (by means of tumor xenografts in nude mice). Herein,
RHPN1
-AS1
expression was found to be significantly upregulated in OS tissues and cell lines. The elevated expression of
RHPN1
-AS1
closely correlated with the tumor size, TNM stage, distal metastasis and shorter overall survival in patients with OS. The depletion of
RHPN1
-AS1
restrained OS cell proliferation, migration, and invasion, and exerted proapoptotic effects in vitro. Furthermore, the knockdown of
RHPN1
-AS1
effectively reduced the tumor growth of OS cells in vivo. As for the mechanism,
RHPN1
-AS1
increased snail family zinc finger 2 (SNAI2 also known as SNAIL2) expression by acting as a competing endogenous RNA of miR-506. Notably, increasing the amount of miR-506 partially reversed the effects of the
RHPN1
-AS1
downregulation on OS cells. In conclusion,
RHPN1
-AS1
contributes to the malignancy of OS cells in vitro and in vivo, largely via upregulation of the miR-506-SNAI2 axis output.
...
PMID:Long noncoding RNA RHPN1-AS1 exerts pro-oncogenic actions in osteosarcoma by functioning as a molecular sponge of miR-506 to positively regulate SNAI2 expression. 3240 Nov 34